Advanced prostate cancer radiotherapy to cut sessions from 20 to five
England's National Health Service has announced it will move localized prostate cancer treatment from a 20-session radiotherapy schedule to a high-precision five-session schedule. According to the BBC, the new approach, known as stereotactic body radiotherapy or SBRT, will compress treatment to a week and a half while preserving clinical effectiveness.
SBRT is an intensity-modulated beam technique guided by computed tomography that targets the tumor with millimetric precision. Conventional radiotherapy spreads the dose across many smaller daily fractions; SBRT delivers higher doses per session without damaging surrounding tissue, shortening the overall course.
NHS England said the new schedule will cover roughly 10,000 men a year. Reducing hospital trips from 20 to five materially cuts travel burden and time off work. Approval by the National Institute for Health and Care Excellence (NICE) accelerated the rollout.
The clinical evidence comes from the multi-centre PACE-B trial, which found five-session SBRT non-inferior to 20-session conventional radiotherapy for long-term control rates in low- and intermediate-risk prostate cancer. Side-effect profiles were broadly comparable.
Urology and oncology specialists frame the shorter schedule as a quality-of-life win. Royal Marsden Hospital consultant oncologist Prof Nick Van As told the BBC the compressed course is 'a huge convenience for patients balancing work and family responsibilities.'
The economic case also stacks up. NHS planners argue that fewer scheduled sessions free up linear accelerator (linac) capacity, which can then be redirected toward other patients. That gain is being used as a lever to bring down treatment waiting lists.
The protocol will not suit every patient. NHS guidance specifies that high-risk locally advanced tumors, or cases requiring pelvic nodal treatment, will continue on standard fractionation. Patient selection is being made by multidisciplinary teams.
Prostate cancer is the most common cancer in men in the UK, with about 52,000 new cases diagnosed each year. NHS figures cited by the BBC indicate a substantial share are caught at an early stage, and radiotherapy remains a primary treatment option alongside surgery.
Internationally, Australia, Canada and the Nordic countries had already standardized similar short-course SBRT schedules over the past few years. England now becomes one of the first major European health systems to adopt the approach as a system-wide policy.
NHS England said the rollout will be staged across oncology centres nationally and clinician training programmes are underway. Patient advocacy groups are awaiting revised guidelines in the coming weeks. This is not medical advice; consult your doctor on treatment decisions.
Read next
World's largest opioid review finds they often do not work
The largest review yet of opioid use in chronic pain has concluded that the drugs often deliver disappointing results across many clinical situations, Science Daily reports. The researchers say prescribing practices should be revisited.
Doctors and the NHS could be sued for mistakes made by AI tools, report warns
According to the Guardian, a new Medical Protection Society report finds that doctors and NHS services could be sued over mistakes made by AI tools used in clinical practice. The report calls for an urgent update to insurance and liability frameworks.
Tea benefits your health and longevity — how you drink it matters
A new international study reported by Science Daily finds regular tea drinking may reduce cardiovascular risk and all-cause mortality. The researchers stress, however, that the effect depends on daily dose, preparation style and whether you add milk or sugar.
Weight-loss drugs drive global whey protein supply toward shortage
Global demand for whey protein is hitting record levels as millions of patients on GLP-1 weight-loss drugs turn to high-protein diets to offset muscle loss, the Guardian reports. Suppliers say production capacity is already pushed close to its limits.
FDA approves first new sunscreen ingredient in over 25 years
The US Food and Drug Administration has cleared bemotrizinol, a broad-spectrum UVA-UVB filter long used in Europe, for the American market. As reported by STAT News, it is the first new sunscreen active ingredient to receive FDA approval since 1999.
